« Back
Home /
BMX-IN-1

BMX-IN-1

Item no.	HY-80002-25mg
Manufacturer	MedChem Express
CASRN	1431525-23-3
Amount	25 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 25 mg 2 mg 50 mg 5 mg
Category	Oncology Neuroscience Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Bladder Cancer Colorectal Cancer Bone Cancer
Type	Inhibitors
Specific against	other
Purity	99.04
Citations	[1]Feiyang Liu , et al. Discovery of a Selective Irreversible BMX Inhibitor for Prostate Cancer. ACS Chem. Biol., DOI: 10.1021/cb4000629
Smiles	O=C1N(C2=C(C=C1)C=NC3=CC=C(C4=CC=C(NS(=O)(C)=O)C=C4)C=C32)C5=CC=C(C)C(NC(C=C)=O)=C5
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	BMX kinase inhibitor
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	BMX Kinase; Btk
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	524.59
Product Description	BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX) that targets Cys496 in the BMX ATP binding domain with an IC50 of 8 nM, also targets the related Bruton’s tyrosine kinase (BTK) with an IC50 value of 10.4 nM, but is more than 47-656-fold less potent against Blk, JAK3, EGFR, Itk, or Tec activity.
Manufacturer - Research Area	Cancer
Solubility	DMF: 10 mg/mL (ultrasonic)\|DMSO: 8.33 mg/mL (ultrasonic)
Manufacturer - Pathway	Protein Tyrosine Kinase/RTK
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-80002-25mg-safety-datasheet.pdf